Meeting
2016 ASCO Annual Meeting
A phase I/II trial of enzalutamide plus the glucocorticoid receptor antagonist mifepristone for patients with metastatic castration resistant prostate cancer (mCRPC).
Authors
Russell Zelig Szmulewitz
The University of Chicago, Chicago, IL
Russell Zelig Szmulewitz , Chadi Nabhan , Peter H. O'Donnell , Jacob Kach , Theodore Karrison , Elia Martinez , Walter Michael Stadler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02012296
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5091)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5091
Abstract #
TPS5091
Poster Bd #
439a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2020 Genitourinary Cancers Symposium
Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Anthony Serritella
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
First Author: David James VanderWeele